Cardiac Output and Oxygen Delivery Responses to Sotatercept in Pulmonary Arterial Hypertension
Open Access
- 1 October 2026
- journal article
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Abstract
Sotatercept, a first‐in‐class activin signaling inhibitor, improves pulmonary vascular hemodynamics and clinical outcomes in pulmonary arterial hypertension (PAH). However, despite reductions in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR), cardiac output (CO) does not generally increase, and some patients experience a decline in CO, a finding of unclear clinical significance. We sought to characterize the heterogeneity of CO responses to sotatercept in PAH and to determine whether incorporating oxygen delivery (DO 2 ) provides additional insight into the physiological significance of these changes. We retrospectively analyzed PAH patients who underwent right heart catheterization before and during sotatercept therapy (median 7.3 months, IQR 4.8, 9.3). Hemodynamic, echocardiographic, hematologic, and clinical parameters were collected, including functional class, 6‐min walk distance (6MWD) and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). Patients were dichotomized by CO response (decreased vs. maintained), and DO 2 was calculated at each catheterization. A total of 56 patients were included. While most demonstrated reductions in PVR and mPAP, 63% experienced decreased CO. Improvements in 6MWD and NT‐proBNP were similar between groups, and hemoglobin increased comparably. However, among patients with decreased CO, 63% had a concomitant decline in DO 2 accompanied by worsening 6MWD and a reduced NT‐proBNP response. In this real‐world cohort, over half of sotatercept‐treated PAH patients experienced reduced CO despite overall hemodynamic and clinical improvement. Concomitant reductions in DO 2 identify a subgroup with worse functional outcomes. These findings suggest that DO 2 adds additional information beyond CO alone when assessing the physiological response to sotatercept.This publication has 27 references indexed in Scilit:
- Sotatercept in Pulmonary Arterial HypertensionJACC, 2026
- Sotatercept for Pulmonary Arterial Hypertension within the First Year after DiagnosisNew England Journal of Medicine, 2025
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for DeathNew England Journal of Medicine, 2025
- Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLARThe Journal of Heart and Lung Transplantation, 2024
- Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic StudyJournal of Cardiac Failure, 2023
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2023
- 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2022
- Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertensionScientific Reports, 2022
- Sotatercept for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2021
- Predicting Survival in Patients With Pulmonary Arterial HypertensionChest, 2019